Emmanuel Mitry
Overview
Explore the profile of Emmanuel Mitry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
3419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dabout V, Mineur L, Tougeron D, Le Malicot K, Gallois C, Phelip J, et al.
Clin Res Hepatol Gastroenterol
. 2024 Dec;
49(1):102514.
PMID: 39674570
Aim Of The Study: The management of synchronous metastatic rectal cancer (SMRC) is complex and multimodal, involving chemotherapy, surgery and/or radiotherapy. The aim of this study was firstly to confirm...
2.
Izaaryene J, Grange R, Habouzit V, Grange S, Orsini B, Dassa M, et al.
Eur Radiol
. 2024 Nov;
PMID: 39572449
Objectives: To evaluate the oncological efficacy and complications of cryoablation (CA) in treating lung metastases from colorectal cancer (CRC) at the lung periphery. Materials And Methods: The inclusion criteria for...
3.
Meillat H, Weets V, Saadoun J, Tyran M, Mitry E, Illy M, et al.
Eur J Surg Oncol
. 2024 Sep;
50(11):108639.
PMID: 39241510
Introduction: Local excision (LE) for good responders after chemoradiotherapy (CRT) for rectal cancer is oncologically safe. Although the GRECCAR 2 trial did not demonstrate any advantages in morbidity, it provided...
4.
Van Laethem J, Borbath I, Prenen H, Geboes K, Lambert A, Mitry E, et al.
Lancet Oncol
. 2024 Jun;
25(7):853-864.
PMID: 38834087
Background: Current systemic therapies for metastatic pancreatic ductal adenocarcinoma are associated with poor outcomes with a 5-year overall survival rate under 5%. We aimed to assess the safety and antitumour...
5.
Gouton E, Gilabert M, Launay S, Loir E, Tyran M, Rochigneux P, et al.
Front Oncol
. 2024 Jan;
13:1326676.
PMID: 38260832
Background: Brain metastases (BM) are rare in pancreatic ductal adenocarcinoma (PDAC) and little data exists concerning these patients and their outcomes. Aim: We aimed to analyze the management, practices, and...
6.
Meillat H, Garnier J, Palen A, Ewald J, de Chaisemartin C, Tyran M, et al.
World J Gastrointest Surg
. 2023 Dec;
15(11):2619-2626.
PMID: 38111764
Background: Rectal sparing is an option for some rectal cancers with complete or good response after chemoradiotherapy (CRT); however, it has never been evaluated in patients with metastases. We assessed...
7.
Marx M, Caillol F, Godat S, Poizat F, Oumrani S, Ratone J, et al.
Ann Gastroenterol
. 2023 Nov;
36(6):686-693.
PMID: 38023974
Background: Current guidelines consider observation a reasonable strategy for G1 or G2 nonfunctional pancreatic neuroendocrine tumors (nf pNETs) ≤2 cm. We aimed to characterize their natural behavior and confront the...
8.
Nicolle R, Bachet J, Harle A, Iovanna J, Hammel P, Rebours V, et al.
J Clin Oncol
. 2023 Nov;
42(9):1067-1076.
PMID: 37963313
Purpose: GemPred, a transcriptomic signature predictive of the efficacy of adjuvant gemcitabine (GEM), was developed from cell lines and organoids and validated retrospectively. The phase III PRODIGE-24/CCTG PA6 trial has...
9.
Alfano M, Garnier J, Palen A, Ewald J, Piana G, Poizat F, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958326
No codified/systematic surveillance program exists for borderline/locally advanced pancreatic ductal carcinoma treated with neoadjuvant FOLFIRINOX and a secondary resection. This study aimed to determine the trend of recurrence in patients...
10.
Boige V, Blons H, Francois E, Abdelghani M, Phelip J, Le Brun-Ly V, et al.
JAMA Netw Open
. 2023 Sep;
6(9):e2333533.
PMID: 37721754
Importance: The optimal maintenance strategy after induction chemotherapy with anti-epidermal growth factor receptor antibody for patients with RAS wild-type metastatic colorectal cancer (mCRC) remains to be debated. Objective: To evaluate...